Esbriet seems to have diminishing therapeutic effect after six months of treatment and possibly no benefit after one year in idiopathic pulmonary fibrosis patients with advanced disease, a Greek retrospective study shows.
The study, “Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study,” appeared in the journal Pulmonary Pharmacology & Therapeutics.
Esbriet, developed by Genentech, is an anti-fibrotic therapeutic whose efficacy was proven in five randomized multicenter clinical trials with IPF patients of mild-to-moderate disease severity. However, its efficacy in patients with more advanced disease requires further studies.
Researchers at the Sotiria Medical School at the University of Athens performed a retrospective multicenter study of IPF patients with severe lung function impairment to investigate Esbriet’s safety and efficacy in this particular patient population.
